Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia

• Status: Completed
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

To demonstrate the efficacy, safety and tolerability of 10 mg oral vardenafil (BAY 38-9456) compared to placebo for a period of 12 weeks in men with erectile dysfunction (ED)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Vardenafil Dihydrochloride

Criteria

Inclusion Criteria:

• Age: 20 years and older- Males with erectile dysfunction

• Stable heterosexual relationship Exclusion Criteria:

• Primary hypoactive sexual desire

• History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months- Nitrate use

• Other exclusion criteria apply according to the Summary of Product Characteristics